Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. - Wikidata - awgldk - TriplyDB

Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.

Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.

http://www.wikidata.org/entity/Q45110054

about

Oncolytic viruses as therapeutic cancer vaccines Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy Oncolytic virotherapy for human malignant mesothelioma: recent advances The known unknowns of the human dendritic cell network The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications Trial Watch:: Oncolytic viruses for cancer therapy The plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functions Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.Measles to the Rescue: A Review of Oncolytic Measles Virus Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8(+) T-cell Activation Against Tumors.The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses Viral oncolysis - can insights from measles be transferred to canine distemper virus?Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.Human plasmacytoid dendritic cells: from molecules to intercellular communication network Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Antitumor Virotherapy by Attenuated Measles Virus (MV).Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Viral cancer therapies: are they ready for combination with other immunotherapies?Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases.Therapy-induced microenvironmental changes in cancer.Potential and clinical translation of oncolytic measles viruses.Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes.A subset of human plasmacytoid dendritic cells expresses CD8α upon exposure to herpes simplex virus type 1.Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responses.Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.

P2860

Q21245758-D846B310-889B-4736-BE11-DF2CBF370C8F Q26774345-8F81F1AA-DC9A-4483-955C-71C961DDCD85 Q26826590-1E27945C-A3BD-42C7-9E0C-284F574C11A0 Q26865854-3403EA30-5498-44CE-9F3F-D67DFF2396A4 Q27002660-78C6E7F5-BF4E-4682-8BB8-C3377750D2D8 Q27021951-01883F87-DFF3-4AE5-9E69-1AA00ED5F9C7 Q27023380-95A1E7B7-21C6-4F5A-9C51-042D2E0EE2B5 Q27340224-545D7141-F3B6-474D-933C-74D34090687F Q28072097-DF1130A5-1B62-4ADF-A9C9-20D7BC962F56 Q30358614-6DB8AA8C-DB3A-4F35-BFFB-3703770FFD4C Q33820699-5FEF7033-5647-46FA-A814-19B5047571DD Q33820717-DDCE17A4-BE90-4ED1-A408-67EE37AE80DE Q33899522-876277C0-BD89-4E6F-802A-E0904057B415 Q35657822-02124008-0BBC-4657-AFCB-D466CE270902 Q36250723-14451010-BA13-4576-9376-AD4700098EE0 Q36413058-20125856-9B3F-493F-B584-C36027D055B4 Q36821243-FAB6EE4B-1FF9-438A-A8A8-056F0089A66A Q37185612-B5A28B43-7933-4B5F-AAA2-294DA2740E86 Q38166716-DAA4A7FC-5D1B-472E-A2DD-65AD2F5A6F81 Q38176613-F3B3E503-0F48-4931-A306-D6806BA2C0D0 Q38208315-68F0AF17-F454-4815-9F03-054CCECB09DC Q38212137-7E2BF503-9B01-45DB-A46D-4D2E2E7D70C3 Q38241666-EE763D2C-077D-47FA-B82A-CC99BAFBABD0 Q38647011-42E6175C-F812-48CB-B952-30DC3B0C30DB Q38720050-9DA038EC-2868-4EC8-AAA1-0EF4D02E2DFA Q38756772-BD6F2CF5-F2F7-4D4C-81CD-A0FAFCA1A80A Q38764947-5C14582B-06AD-4759-B378-37E1A2A65733 Q38804011-28538711-3FB6-46EC-BE24-E6CEB34178A6 Q38850997-3FB233F7-4C88-4B56-942D-0B95F3224316 Q38940653-177419AC-79DC-43E4-8A68-2A6724119FDC Q39008033-0ECABD32-DFAE-45B0-9F8C-886BE07D6735 Q39467892-234D2D97-0839-4883-8F2F-E67A382CB8DD Q40200208-9A74F294-9F76-457E-8310-EF1B99FD7725 Q40336053-63774C6A-D7D3-45EB-8823-98F23115AE17 Q40342539-62AC9276-FA92-414A-81A3-F06F3D1DA135 Q41155777-F760BC1F-69C9-4364-9F4D-22BE91EDC219 Q41220068-550C8065-6ED5-4933-A64E-A3B5C28E4A47 Q41699675-78147214-8C36-4BC6-8E20-F082775BD947 Q42204967-08E34A0D-14B2-4835-A45F-14B34174F8E8 Q45323818-57ECF9AE-A58D-4F6D-875E-D3456D22527F

P2860

Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.

http://www.wikidata.org/entity/Q45110054

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@en

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@nl

type

label

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@en

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@nl

prefLabel

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@en

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@nl

P1433

Q45110054-E9253E42-E899-4EC4-872D-3B2ED4E0312A

P1476

Q45110054-EB439CB9-DDC3-4E1A-B434-61D8550FA444

P2093

Q45110054-1C5A4820-CE23-46B6-BD70-A1AAB43A6E64

Q45110054-8474B795-0085-4E93-AF01-0E6ACD72CCB6

Q45110054-C3A34FBF-2EF5-47CD-BC15-01C3883A0869

Q45110054-CDE09E74-D86E-45CF-A850-FA309E0268DD

Q45110054-D710386D-932A-4B9D-8801-F1D90DD60353

Q45110054-E3BF9AEC-0CCB-402F-9BBB-57B6272A5821

Q45110054-FA8CDEEA-837B-4425-881C-4AA99219A1A9

P304

Q45110054-30B9174A-AA02-479F-87D2-F857C57E8DE6

P31

Q45110054-FDFBF7F6-45B7-4955-9800-A43C2D83D1F7

P356

Q45110054-4B868E38-BC79-4841-B171-CE13207781B6

P407

Q45110054-A268ADBE-111A-44A2-8E47-9202E5384608

P433

Q45110054-3FAF34E3-C3FA-48B2-B159-7AECFD387F1A

P478

Q45110054-6345F3C8-ED9F-445E-A36C-31D586820D16

P50

Q45110054-31527E6B-34B9-4620-84B0-42C652166BEE

P577

Q45110054-D319BD45-274F-4C14-AD27-2AA1E43528C7

P5875

Q45110054-F13F1754-EC5D-4D25-8DE9-4F9637A5F7E4

P698

Q45110054-B4F59840-A664-42CC-8FA9-356F323230A5

P921

Q45110054-A468EFEA-FF17-4EA5-B0AE-362B6D1FD64D

P356

1078-0432.CCR-12-2733

P1433

Clinical Cancer Research

P1476

Measles virus vaccine-infected ...... plasmacytoid dendritic cells.

@en

P2093

Chantal Combredet

http://www.w3.org/2001/XMLSchema#string

David Roulois

http://www.w3.org/2001/XMLSchema#string

Jean-Baptiste Guillerme

http://www.w3.org/2001/XMLSchema#string

Jean-François Fonteneau

http://www.w3.org/2001/XMLSchema#string

Jérémie Ménager

http://www.w3.org/2001/XMLSchema#string

Marc Gregoire

http://www.w3.org/2001/XMLSchema#string

Nicolas Boisgerault

http://www.w3.org/2001/XMLSchema#string

P304

1147-1158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2733

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Frédéric Tangy

P577

2013-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234824540

http://www.w3.org/2001/XMLSchema#string

P698

23339127

http://www.w3.org/2001/XMLSchema#string

P921